Maze Therapeutics(MAZE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MAZE Maze Therapeutics

Trading 08-26 12:16:16 EDT

29.40

-1.02

-3.35%

High30.40	Low29.33	Vol90.85K
Open30.26	D1 Closing30.42	Amplitude3.52%
Mkt Cap1.62B	Tradable Cap1.10B	Total Shares55.25M
T/O2.71M	T/O Rate0.24%	Tradable Shares37.25M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MAZE","market":"US","secType":"STK","nameCN":"Maze Therapeutics","latestPrice":29.4,"timestamp":1787760947813,"preClose":30.42,"halted":0,"volume":90846,"delay":0,"changeRate":-0.033530571992110556,"floatShares":37250300,"shares":55248700,"eps":-2.517242,"marketStatus":"Trading","change":-1.02,"latestTime":"08-26 12:16:16 EDT","open":30.26,"high":30.4,"low":29.33,"amount":2706618.120696,"amplitude":0.035174,"askPrice":29.44,"askSize":48,"bidPrice":29.38,"bidSize":22,"shortable":3,"etf":0,"ttmEps":-2.517242,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787774400000},"marketStatusCode":2,"adr":0,"listingDate":1738299600000,"exchange":"NASDAQ","adjPreClose":30.42,"postHourTrading":{"tag":"盘后","latestPrice":30.42,"preClose":30.42,"latestTime":"16:20 EDT","volume":7465,"amount":227085.3,"timestamp":1787689200378,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.718232,"impliedVol":0.6395,"impliedVolPercentile":0.3924},"requestUrl":"/m/hq/s/MAZE/wiki","defaultTab":"wiki","newsList":[{"id":"2660324524","title":"Maze Therapeutics Director Paula A. Johnson Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2660324524","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660324524?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:46","pubTimestamp":1786999574,"startTime":"0","endTime":"0","summary":"Maze Therapeutics director Paula A. Johnson files initial beneficial ownership statementMaze Therapeutics director Paula A. Johnson filed an initial Form 3 on Aug. 17, 2026.Disclaimer:This news brief ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL78z2DV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660328084","title":"Maze Therapeutics Names Paula Johnson, Sophie Kornowski to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2660328084","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660328084?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:18","pubTimestamp":1786997890,"startTime":"0","endTime":"0","summary":"Maze Therapeutics names Paula Johnson, Sophie Kornowski to board of directorsMaze Therapeutics named Paula Johnson and Sophie Kornowski to its board of directors.Johnson is president of Wellesley Coll","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL87kkJn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659712190","title":"Maze Therapeutics President, R&D and CMO Harold Bernstein Disposes of USD 445,522 Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2659712190","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659712190?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:58","pubTimestamp":1786741080,"startTime":"0","endTime":"0","summary":"Maze Therapeutics President, R&D and CMO Harold Bernstein disposes of USD 445,522 common sharesMaze Therapeutics President, R&D and CMO Harold Bernstein sold 16,142 common shares on Aug. 13 at USD 27.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL3LPRJ9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics President, R&D and CMO Harold Bernstein Disposes of USD 445,522 Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659614160","title":"Maze Therapeutics Adds Paula Johnson, Sophie Kornowski to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2659614160","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659614160?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:49","pubTimestamp":1786654155,"startTime":"0","endTime":"0","summary":"Maze Therapeutics adds Paula Johnson, Sophie Kornowski to boardMaze Therapeutics appointed Paula Johnson and Sophie Kornowski to its board.Johnson is president of Wellesley College, a cardiologist, an","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL7LTtBJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BSNM7G36.USD","LU2456880835.USD","BMED","IE00BJT1NW94.SGD","BCDF","MAZE","LU0820561818.USD","BK4534","LU0689626769.HKD","LU1778281490.HKD","MEDX","LU0787776722.HKD","SGXZ80539844.SGD","IHE","IE000SO60NU8.SGD","LU1244550494.USD","LU0820561909.HKD","IE00BKPKM429.USD","LU0985320562.USD","LU1732800096.USD","IXJ","IE00BGHQF631.EUR","LU1043141123.HKD","LU1894683348.USD","JNJ","LU2112291526.USD","IE00BZ1G4Q59.USD","IE00BVYPNW00.USD","LU0345769128.USD","FHLC","LU0320765646.SGD","LU2471134523.USD","IYH","GDOC","FTXH","LU0689472784.USD","LU2129689431.USD","BK4585","JDOC","TRUH","XLV","LU1066051811.HKD","LU0345770993.USD","PJP","NDAQ","LU0964807845.USD","LU0820562030.AUD","RXL","LU1221951046.USD","VHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659351160","title":"Maze Therapeutics Announces Appointments to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2659351160","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659351160?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:42","pubTimestamp":1786653745,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nTUABH5JRC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659675701","title":"CAMP4 Therapeutics Q2 Loss Per Share Misses Estimates on Non-Cash Derivative Charge","url":"https://stock-news.laohu8.com/highlight/detail?id=2659675701","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659675701?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:22","pubTimestamp":1786652530,"startTime":"0","endTime":"0","summary":"CAMP4 Therapeutics Q2 loss per share misses estimates on non-cash derivative chargeOverviewUS biopharmaceutical developer's Q2 loss per share missed analyst expectationsNet loss widened due to non-cas","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A14P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007","CAMP","ABEO","ELOX","BK4020","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659713511","title":"Legal and Regulatory Risks Threaten Maze Therapeutics’ Funding, Reputation and Path to Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2659713511","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659713511?lang=en_us&edition=fundamental","pubTime":"2026-08-13 14:00","pubTimestamp":1786600849,"startTime":"0","endTime":"0","summary":"Maze Therapeutics, Inc. (MAZE) has disclosed a new risk, in the Regulation category. Maze Therapeutics, Inc. faces a material risk that future liti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/legal-and-regulatory-risks-threaten-maze-therapeutics-funding-reputation-and-path-to-commercialization?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/legal-and-regulatory-risks-threaten-maze-therapeutics-funding-reputation-and-path-to-commercialization?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659823201","title":"Belite Bio Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2659823201","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659823201?lang=en_us&edition=fundamental","pubTime":"2026-08-13 09:55","pubTimestamp":1786586157,"startTime":"0","endTime":"0","summary":"Belite Bio Q2 net loss widens on higher expensesOverviewUS retinal disease drug developer's Q2 net loss widened as R&D and SG&A expenses increasedFDA accepted NDA for tinlarebant with Priority Review ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A01Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELOX","BLTE","MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658974286","title":"Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Maze Therapeutics, Inc. (MAZE) and Immunome (IMNM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658974286","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658974286?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:40","pubTimestamp":1786534824,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Travere Therapeutics (TVTX), Maze Therapeutics, Inc....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-travere-therapeutics-tvtx-maze-therapeutics-inc-maze-and-immunome-imnm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-travere-therapeutics-tvtx-maze-therapeutics-inc-maze-and-immunome-imnm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","MAZE","LU0029874061.USD","LABU","FFTY","BK4007","IMNM","LFSC","BK4137","XLV","TVTX","XBI","BK4563","BK4581","HCSG","BK4588","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658971411","title":"Humacyte Q2 Net Loss Widens on Inventory, Production Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2658971411","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658971411?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:11","pubTimestamp":1786533109,"startTime":"0","endTime":"0","summary":"Humacyte Q2 net loss widens on inventory, production costsOverviewU.S. bioengineered tissue maker's Q2 net loss widened, missing analyst expectationsQ2 product revenue for Symvess rose to $0.4 mln fro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N4490DQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007","BK4563","BK4139","PROK","HUMA","PLRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658971522","title":"Switzerland's Pharvaris Q2 Loss Narrows, Cash Rises to €318 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2658971522","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658971522?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:02","pubTimestamp":1786532528,"startTime":"0","endTime":"0","summary":"Switzerland's Pharvaris Q2 loss narrows, cash rises to 318 mlnOverviewSwitzerland biopharma firm reported Q2 loss per share of 0.70, improving from prior yearCash and equivalents rose to 318 mln, with","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N4490CZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHVS","BK4505","MREO","MAZE","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658979623","title":"Maze Therapeutics: Buy Rating Reaffirmed as Clinical De-Risking Supports Unchanged $110 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2658979623","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658979623?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:36","pubTimestamp":1786530964,"startTime":"0","endTime":"0","summary":"Ananda Ghosh, an analyst from H.C. Wainwright, maintained the Buy rating on Maze Therapeutics, Inc.. The associated price target remains the same w...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/maze-therapeutics-buy-rating-reaffirmed-as-clinical-de-risking-supports-unchanged-110-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/maze-therapeutics-buy-rating-reaffirmed-as-clinical-de-risking-supports-unchanged-110-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658976577","title":"Maze Therapeutics Price Target Maintained with a $46.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2658976577","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658976577?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:11","pubTimestamp":1786529460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MAZE/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658263459","title":"Press Release: MindMaze Therapeutics Appoints Prof. John W. Krakauer as Strategic Advisor","url":"https://stock-news.laohu8.com/highlight/detail?id=2658263459","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658263459?lang=en_us&edition=fundamental","pubTime":"2026-08-12 13:40","pubTimestamp":1786513200,"startTime":"0","endTime":"0","summary":"significant improvements in patient mobility and self-care, a 60%. increase in delivered therapy per day, and 17% higher community discharge. rates compared to standard of care, while 87% of patients found the. -- the establishment of a U.S. headquarters and Patient Experience Center at. -- the announcement earlier this year of a go-to-market partnership with","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE","BK4022","BK4232","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658794584","title":"Maze Therapeutics Q2 EPS $(0.76) Misses $(0.73) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658794584","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658794584?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:36","pubTimestamp":1786480573,"startTime":"0","endTime":"0","summary":"Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.73) by 4.11 percent. This is a 1.3 percent increase over losses of $(0.77) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61128219/maze-therapeutics-q2-eps-0-76-misses-0-73-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics Q2 EPS $(0.76) Misses $(0.73) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658943074","title":"Earnings Flash (MAZE) Maze Therapeutics Posts Q2 Loss $0.76 per Share, vs. FactSet Est of $0.72 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2658943074","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658943074?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:33","pubTimestamp":1786480425,"startTime":"0","endTime":"0","summary":"Earnings Flash (MAZE) Maze Therapeutics Posts Q2 Loss $0.76 per Share, vs. FactSet Est of $0.72 Loss","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658943150","title":"Maze Therapeutics reports Q2 EPS (76c), consensus (70c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658943150","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658943150?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:16","pubTimestamp":1786479407,"startTime":"0","endTime":"0","summary":"“The second quarter was marked by continued operational excellence by our team, with the Phase 2 CIPheR trial of MZE782 in PKU now underway with in...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-reports-q2-eps-76c-consensus-70c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-reports-q2-eps-76c-consensus-70c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658943564","title":"Maze Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2658943564","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658943564?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:16","pubTimestamp":1786479398,"startTime":"0","endTime":"0","summary":"Maze Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings SummaryMaze Therapeutics, Inc.MAZE.OQreported a quarterly adjusted loss of 76 cents per share for the quarter ended Jun","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL8N448225:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658948377","title":"Maze Therapeutics Rugi Bersih Q2 FY26 Melebar Ke USD 44,7 Juta; Rugi Per Saham Naik Ke USD 0,76","url":"https://stock-news.laohu8.com/highlight/detail?id=2658948377","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658948377?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:02","pubTimestamp":1786478567,"startTime":"0","endTime":"0","summary":"Maze Therapeutics rugi bersih Q2 FY26 melebar ke USD 44,7 juta; rugi per saham naik ke USD 0,76Maze membukukan rugi bersih USD 44,73 juta pada kuartal II, melebar dari USD 33,68 juta setahun sebelumny","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL3ZhWxJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","BK4112","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4585","BCDF","MAZE","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU0314104364.USD","SG9999014039.USD","BK4007","BK4588","IE00B3QW5Z07.USD","NDAQ","SG9999014021.USD","LU2210150020.SGD","LU2210149790.SGD","IE00BKPKM429.USD","LU2095319765.USD","SG9999014005.SGD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658948336","title":"Maze Therapeutics Inc Q2 Income from Operations USD -48.035 Million VS. Ibes Estimate USD -45.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658948336","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658948336?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:01","pubTimestamp":1786478460,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLXT0B0GS:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mazetx.com;ir.mazetx.com","stockEarnings":[{"period":"1week","weight":0.0443},{"period":"1month","weight":0.099},{"period":"3month","weight":0.1678},{"period":"6month","weight":-0.3364},{"period":"1year","weight":1.2855},{"period":"ytd","weight":-0.2657}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0365},{"period":"3month","weight":0.0206},{"period":"6month","weight":0.1111},{"period":"1year","weight":0.1921},{"period":"ytd","weight":0.1232}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"Maze Therapeutics","nameEN":"Maze Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Maze Therapeutics(MAZE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Maze Therapeutics(MAZE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Maze Therapeutics,MAZE,Maze Therapeutics股票,Maze Therapeutics股票老虎,Maze Therapeutics股票老虎国际,Maze Therapeutics行情,Maze Therapeutics股票行情,Maze Therapeutics股价,Maze Therapeutics股市,Maze Therapeutics股票价格,Maze Therapeutics股票交易,Maze Therapeutics股票购买,Maze Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Maze Therapeutics(MAZE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Maze Therapeutics(MAZE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction